LOGO
  • About
  • Science
  • Patents
  • Academic Program
  • Blog
  • Industry News
  • e·Meditation
  • English
    • English
    • Русский
    • العربية
    • Deutsch
    • Español
    • Français
    • हिन्दी
    • 日本語
    • 한국어
    • Polski
    • Português
    • 简体中文
  1. Home
  2. blog

Cumulus Neuroscience and Muse by Interaxon bring validated at‑home sleep EEG to CNS clinical trials

Cumulus Neuroscience and Muse by Interaxon announced on July 6 that Muse’s at‑home EEG will feed validated overnight sleep recordings into Cumulus’s NeuLogiq® platform for use in CNS clinical trials. The release did not name specific trials or give a rollout timeline.

7 Jul 2026

Theta-burst magnetic stimulation improved communication in children with autism in 194-child trial

A randomized BMJ trial of 194 children (average age ~6.5) found that a five-day course of theta-burst transcranial magnetic stimulation improved social communication and language, with effects still seen at one month and no serious adverse events reported.

7 Jul 2026

Tulsa team tests low‑intensity focused ultrasound for treatment‑resistant depression

Tulsa’s Laureate Institute for Brain Research is running a federally funded trial using low‑intensity focused ultrasound to probe and modulate deep brain circuits in people with treatment‑resistant depression; investigators say the work is exploratory and not a cure.

7 Jul 2026

Three tVNS clinical trials listed as recruiting for aphasia, alcohol dependence and post‑aSAH care

Three recruiting clinical trials are testing transcutaneous vagus nerve stimulation (tVNS): an ear‑device plus speech therapy for post‑stroke aphasia, neuromodulation with mindfulness for alcohol dependence, and a tolerability study after aneurysmal subarachnoid haemorrhage.

7 Jul 2026

Read-only wearables are giving way to read-write devices that actively intervene in the body

Companies including Vibe Science and Elemind are pushing wearables from passive sensing toward devices that both read physiology and deliver timed interventions, raising questions about evidence, safety, and integration with clinical systems.

7 Jul 2026

Fluent develops under‑scalp BCI to decode attempted speech

Fluent, a University of Melbourne spinout, is developing an insertable under‑scalp BCI that records motor‑cortex activity and uses machine learning to convert attempted speech into text or audio. The company reports preliminary human testing and says clinical studies are scheduled later this year.

2 Jul 2026

Aid for brain-bleed recovery receives FDA Breakthrough Device Designation

Aurenar’s V-Link earbud device earned FDA Breakthrough Device designation to reduce cerebral vasospasm after subarachnoid hemorrhage, based on early WashU trials showing a 40% drop in vasospasm and improved 90-day outcomes in 27 patients.

2 Jul 2026

BRYM raises €650,000 to build wearable EEG headband for neurofeedback

Stockholm startup BRYM raised €650,000 in a pre-seed round led by Lotus One Investment to build a proprietary wearable EEG headband and expand its gamified neurofeedback platform; early pilots in automotive manufacturing reportedly cut operator errors by 46%.

2 Jul 2026

Sequential bilateral TMS yields ~70% response in adolescents and young adults with treatment‑resistant depression

A peer‑reviewed study in Transcranial Magnetic Stimulation reported ~70% response and 42% remission in 33 adolescents and young adults with treatment‑resistant depression using a sequential bilateral TMS protocol that adds a short right‑side iTBS sequence to standard 10 Hz left stimulation.

30 Jun 2026

Meta unveils Brain2Qwerty v2: MEG-based brain‑to‑text hits 61% word accuracy on early data

Meta announced Brain2Qwerty v2, a MEG‑based non‑invasive brain‑to‑text system that achieved 61% average word accuracy on data from nine volunteers and plans to release training code and a dataset as part of its Digital Brain Project.

30 Jun 2026

How brain–computer interface chips work and where they are used

A concise explainer of brain–computer interface chips: what they are, how they read neural signals, common implant options and clinical uses for mobility and communication, and the main technical and ethical issues.

30 Jun 2026

Paper shows Soto–Alexandrov vestibular neuron model reduces to second-order near Hopf point

A Moscow University Mechanics Bulletin paper demonstrates that the Soto–Alexandrov third‑order model of vestibular afferent neurons can be reduced to a second‑order system near an Andronov–Hopf bifurcation by approximating the potassium inactivation variable hK as constant (≈0.875). The reduction preserves the model’s limit‑cycle projection and simplifies analysis of bistability and state transitions.

29 Jun 2026

Eight weeks of device-guided slow breathing reduces sympathetic nerve spikes in veterans with PTSD

A randomized, double-blind trial of 25 veterans with PTSD found that eight weeks of daily device-guided slow breathing reduced muscle sympathetic nerve responses to an acute mental-stress task, though resting blood pressure and heart rate were unchanged.

29 Jun 2026

VR plus nerve stimulation improves arm and hand recovery after stroke

A 2026 randomized feasibility trial in Nature Medicine found that MultiSensy — immersive VR synchronized with transcutaneous electrical nerve stimulation — produced larger improvements in upper-limb motor scores, functional use, and touch perception than conventional rehab in 34 patients more than three months after stroke.

29 Jun 2026

Common constipation drug improved memory and attention in people with remitted depression

A randomized trial of 50 adults in remission from depression found that one week of 2 mg daily prucalopride improved memory, attention and processing speed versus placebo, with no significant short-term side effects. The study appears in Psychological Medicine (15 June 2026, DOI linked).

27 Jun 2026

Vagus nerve implicated in α‑synuclein spread in Parkinson’s and in cholinergic/inflammatory pathways in Alzheimer’s

Recent experimental and neuropathology studies reinforce the vagus nerve’s role in Parkinson’s—where gut‑origin α‑synuclein can travel to the brainstem—and implicate vagal pathways in Alzheimer’s via cholinergic and inflammatory networks. Early clinical trials and a 2025 meta‑analysis show promising but inconsistent effects for noninvasive VNS.

27 Jun 2026
← 1 2 3 4 5 6 7 8 9 10 ... 13 14 →

Search

About Us

Stay updated with the latest events and innovations from BrainPatch.ai by following our news and updates!

Categories

  • Announcements
  • Blog
  • Articles
  • Industry News
  • Science News

Archives

  • January 2022
  • January 2024
  • January 2025
  • January 2026
  • February 2023
  • February 2024
  • February 2026
  • March 2023
  • March 2024
  • March 2026
  • April 2025
  • April 2026
  • May 2020
  • May 2022
  • May 2026
  • June 2019
  • June 2022
  • June 2023
  • June 2025
  • June 2026
  • July 2022
  • July 2024
  • July 2025
  • July 2026
  • August 2022
  • August 2025
  • September 2020
  • September 2024
  • September 2025
  • October 2019
  • October 2021
  • October 2022
  • October 2024
  • October 2025
  • November 2022
  • December 2021
  • December 2022

🍪 We use cookies

We use cookies to enhance your browsing experience and analyze our traffic. Privacy Policy

BrainPatch® and e·Meditation® is a registered trademarks of BrainPatch Ltd.

Follow Us

Site map

  • Home
  • About
  • News
  • Industry News
  • Companies
  • Science
  • Patents
  • Academic Program
  • e·Meditation Device

Follow Us

  • Facebook
  • Instagram
  • LinkedIn
  • X
  • sales@brainpatch.ai
  •  

Contact Us

  • BrainPatch Limited,
    9 Hills Road, CB2 1GE, Cambridge, United Kingdom
    Company Number 11271285
    VAT GB310938419
  • BrainPatch Limited,
    Landscape House, Baldonnell Business Park, Baldonnell, Dublin, D223PK7, Ireland
    Company Number 678405

© 2026 All rights reserved. Created by: BrainPatch Ltd.

Privacy Policy